Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Theriva Biologics Inc TOVX

Healthcare Biotechnology

Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade... see more

Add To Watchlist

Recent & Breaking News (NYSEAM:TOVX)

Synthetic Biologics Reports that Licensor Cedars-Sinai Finds Eradication of Gut Methane Improves Insulin Sensitivity and Lipid Profiles in Study of Pre-Diabetic, Obese Patients

PR Newswire June 25, 2014

Synthetic Biologics and Enterome Bioscience Collaborate on Microbiome Research to Support Synthetic Biologics' C. difficile Program

PR Newswire June 10, 2014

Synthetic Biologics to Present at the 3rd Annual Marcum LLP MicroCap Conference

PR Newswire May 20, 2014

Synthetic Biologics Reports First Quarter 2014 Financial Results and Operational Highlights

PR Newswire May 15, 2014

Synthetic Biologics to Report First Quarter 2014 Financial Results

PR Newswire May 9, 2014

Synthetic Biologics Announces Recent International Patents that Bolster its C. difficile Program

PR Newswire May 8, 2014

Synthetic Biologics to Discuss Phase II Results of Oral Estriol Candidate Trimesta(TM) for Relapsing-Remitting Multiple Sclerosis in Women

PR Newswire April 30, 2014

Synthetic Biologics Reports UCLA Announcement of Preliminary Positive Topline Efficacy and Safety Results from Investigator-Led Phase II Study of Trimesta(TM) for Relapsing-Remitting Multiple Sclerosis

PR Newswire April 29, 2014

Synthetic Biologics' Reports Preclinical Data to Support Clinical Development of Novel Pertussis Therapeutic

PR Newswire April 23, 2014

Synthetic Biologics Appoints Mark Pimentel, M.D., Chairman of New Irritable Bowel Syndrome Clinical Advisory Board

PR Newswire April 14, 2014

Synthetic Biologics Reports Year End 2013 Financial Results and Operational Update

PR Newswire March 31, 2014

Synthetic Biologics to Report Year End 2013 Financial Results

PR Newswire March 25, 2014

Synthetic Biologics Announces Issuance of U.S. Patent Adding Another Layer of Protection for the Use of Oral Estriol Candidate, Trimesta(TM), for Multiple Sclerosis

PR Newswire March 10, 2014

Synthetic Biologics to Present at the 26th Annual ROTH Conference

PR Newswire March 5, 2014

Synthetic Biologics' Board of Directors Accepts Resignation of Long-Standing Founder and Board Member

PR Newswire February 26, 2014

Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity

PR Newswire February 13, 2014

Synthetic Biologics Announces Rhonda Voskuhl, M.D., to Present Trimesta(TM) Phase II Multiple Sclerosis Clinical Trial Results at the 2014 AAN Annual Meeting

PR Newswire February 10, 2014

Synthetic Biologics to Present at the 2014 BIO CEO & Investor Conference

PR Newswire February 4, 2014

Synthetic Biologics Strengthens Clinical & Regulatory Team to Support Expanding Pipeline of Infectious Disease Programs

PR Newswire January 27, 2014

Synthetic Biologics to Present at the Biotech Showcase(TM) 2014 Conference

PR Newswire January 8, 2014